Horizon Therapeutics (HZNP) Tops Q1 EPS by 20c; Maintains Outlook

Horizon Therapeutics (NASDAQ: HZNP) reported Q1 EPS of $1.34, $0.20 better than the analyst estimate of $1.14. Revenue for the quarter came in at $885.2 million versus the consensus estimate of $874.41 million.

GUIDANCE:

Horizon Therapeutics maintains its FY2022 revenue outlook of $3.9-4 billion, versus the consensus of $3.98 billion.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c